Impairment of FOXM1 expression in mesenchymal cells from patients with myeloid neoplasms, de novo and therapy-related, may compromise their ability to support hematopoiesis

Impairment of FOXM1 expression in mesenchymal cells from patients with myeloid neoplasms, de novo and therapy-related, may compromise their ability to support hematopoiesis

Abstract Bone marrow mesenchymal stem cells (BM-MSCs) exhibit multiple abnormalities in myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML), including reduced proliferative and clonogenic capacity, altered morphology, impaired immunoregulatory properties and capacity to support hematop...

Full description

Bibliographic Details
Main Authors: Giulia Falconi, Elisa Galossi, Emiliano Fabiani, Marco Pieraccioli, Serena Travaglini, Hajro Hajrullaj, Raffaella Cerretti, Raffaele Palmieri, Roberto Latagliata, Luca Maurillo, Maria Teresa Voso
Format: Article
Language:English
Published: Nature Portfolio 2022-12-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-24644-1

Internet

https://doi.org/10.1038/s41598-022-24644-1

Similar Items